Literature DB >> 3292705

Endopeptidase-24.15 is the primary enzyme that degrades luteinizing hormone releasing hormone both in vitro and in vivo.

C J Molineaux1, A Lasdun, C Michaud, M Orlowski.   

Abstract

The concentration of luteinizing hormone releasing hormone (LHRH) (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), which reaches the anterior pituitary via the hypothalamo-hypophyseal portal system, appears to be controlled in part by the rate of LHRH degradation within the hypothalamus and/or pituitary. Specific, active site-directed endopeptidase inhibitors synthesized in our laboratory were used to identify the enzyme(s) involved in LHRH degradation by hypothalamic and pituitary membrane preparations, and by an intact anterior pituitary tumor cell line (AtT20). Incubation of LHRH with pituitary and hypothalamic membrane preparations led to the formation of pGlu-His-Trp (LHRH1-3) as the main reaction product. Under the same conditions, addition to the incubation mixtures of captopril, an inhibitor of the angiotensin converting enzyme, led to accumulation of pGlu-His-Trp-Ser-Tyr (LHRH1-5) and, to a lesser extent, pGlu-His-Trp-Ser-Tyr (LHRH1-6). The degradation of LHRH and the formation of the N-terminal tri- and pentapeptides was blocked by N-[1-(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate (cFP-AAF-pAB), a specific, active site directed inhibitor of endopeptidase-24.15. Some inhibition of LHRH degradation and formation of the N-terminal hexapeptide was also obtained in the presence of N-[1-carboxy-2-phenylethyl]-Phe-p-aminobenzoate (cFE-F-pAB), an inhibitor of endopeptidase-24.11. Similar results were obtained with AtT20 cell membranes and with intact AtT20 cells in monolayer culture. Following cleavage by endopeptidases the C-terminal part of LHRH was rapidly degraded by aminopeptidases. Superactive analogs of LHRH in which Gly6 was replaced by a D-amino acid are resistant to degradation by both endopeptidase-24.11 and -24.15. In vivo, when LHRH was injected directly into the third ventricle of rats, the presence of cFP-AAF-pAB inhibited LHRH degradation. It is concluded that LHRH degradation is primarily initiated by the membrane-bound form of endopeptidase-24.15 to yield pGlu-His-Trp-Ser-Tyr and to a lesser extent by endopeptidase-24.11 to yield pGlu-His-Trp-Ser-Tyr-Gly.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3292705     DOI: 10.1111/j.1471-4159.1988.tb01084.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  17 in total

1.  Mapping sequence differences between thimet oligopeptidase and neurolysin implicates key residues in substrate recognition.

Authors:  Kallol Ray; Christina S Hines; David W Rodgers
Journal:  Protein Sci       Date:  2002-09       Impact factor: 6.725

2.  Congenital idiopathic hypogonadotropic hypogonadism: evidence of defects in the hypothalamus, pituitary, and testes.

Authors:  Gerasimos P Sykiotis; Xuan-Huong Hoang; Magdalena Avbelj; Frances J Hayes; Apisadaporn Thambundit; Andrew Dwyer; Margaret Au; Lacey Plummer; William F Crowley; Nelly Pitteloud
Journal:  J Clin Endocrinol Metab       Date:  2010-04-09       Impact factor: 5.958

3.  Overexpression of the PepF oligopeptidase inhibits sporulation initiation in Bacillus subtilis.

Authors:  Kyoko Kanamaru; Sophie Stephenson; Marta Perego
Journal:  J Bacteriol       Date:  2002-01       Impact factor: 3.490

4.  Endopeptidase 24.15 from rat testes. Isolation of the enzyme and its specificity toward synthetic and natural peptides, including enkephalin-containing peptides.

Authors:  M Orlowski; S Reznik; J Ayala; A R Pierotti
Journal:  Biochem J       Date:  1989-08-01       Impact factor: 3.857

5.  Synthetic inhibitors of endopeptidase EC 3.4.24.15: potency and stability in vitro and in vivo.

Authors:  R A Lew; F Tomoda; R G Evans; L Lakat; J H Boublik; L A Pipolo; A I Smith
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

6.  EP24.15 as a Potential Regulator of Kisspeptin Within the Neuroendocrine Hypothalamus.

Authors:  Nicole C Woitowich; Keith D Philibert; Randy J Leitermann; Manida Wungjiranirun; Janice H Urban; Marc J Glucksman
Journal:  Endocrinology       Date:  2015-12-11       Impact factor: 4.736

7.  Pathways and kinetics of deslorelin degradation in an airway epithelial cell line (Calu-1).

Authors:  Kavitha Koushik; Gangadhar Sunkara; Peter Gwilt; Uday B Kompella
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

8.  GnRH-(1-5) transactivates EGFR in Ishikawa human endometrial cells via an orphan G protein-coupled receptor.

Authors:  Madelaine Cho-Clark; Darwin O Larco; Nina N Semsarzadeh; Florencia Vasta; Shaila K Mani; T John Wu
Journal:  Mol Endocrinol       Date:  2013-01-01

9.  Comparative studies on the affinities of ATP derivatives for P2x-purinoceptors in rat urinary bladder.

Authors:  X Bo; B Fischer; M Maillard; K A Jacobson; G Burnstock
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

10.  Enzymatic degradation of luteinizing hormone releasing hormone (LHRH)/[D-Ala6]-LHRH in lung pneumocytes.

Authors:  X Yang; Y Rojanasakul; L Wang; J Y Ma; J K Ma
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.